Beware clarithromycin-CCB drug interactionDual therapy has renal risks Unnecessary tests driving thyroid cancer epidemicDiagnosis rates vary widely but mortality remains constant Widespread kidney testing too costly Routine screening should focus on high-risk patients BY John Schieszer Renal denervation dilemma Hypertension procedure a bust in major trial Hormone therapy for breast cancer: When is five years enough? Ten-year treatment adds little benefit in early disease Concern raised over stroke risk with aromatase inhibitors Manitoba registry turns up findings not seen in trials PRACTICE GEMS: Ask pharma reps for trade-size samples New Canadian guidelines for managing castration-resistant prostate cancer Addiction treatment: So much more than prescription heroin Video: Dr. Mike Evans on lower back pain First Previous 1662 1663 1664 1665 1666 Next Last
